Core biodecontamination revenues increased by 13%, driving a material improvement on operating margins to 10% and strong EPS growth of 78%. Having upgraded our FY18/19 EPS forecasts by 18% & 16% respectively in January, we make no further changes at this early stage in the year. The shares continue to trade at a material discount to peers and we see further upside scope on growth, forecast upside and potential cash returns.
07 Mar 2018
Strong in line results, outlook remains positive
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong in line results, outlook remains positive
Bioquell (BQE:LON) | 0 0 (-1.6%) | Mkt Cap: 77.0m
- Published:
07 Mar 2018 -
Author:
Chris Glasper -
Pages:
3
Core biodecontamination revenues increased by 13%, driving a material improvement on operating margins to 10% and strong EPS growth of 78%. Having upgraded our FY18/19 EPS forecasts by 18% & 16% respectively in January, we make no further changes at this early stage in the year. The shares continue to trade at a material discount to peers and we see further upside scope on growth, forecast upside and potential cash returns.